更新于：2024-11-01

Glioma of Brain, Familial

家族性脑胶质瘤

更新于：2024-11-01

基本信息

别名

GLIOMA OF BRAIN, FAMILIAL、GLM、Glioma of Brain, Familial

+ [1]

简介-

关联

项与家族性脑胶质瘤相关的药物

Trametinib dimethyl sulfoxide

二甲基亚砜曲美替尼

靶点

MEK1 x MEK2

作用机制

MEK1抑制剂 [+1]

在研机构

Novartis Europharm Ltd. [+11]

原研机构

GSK Plc

在研适应症

低级神经胶质瘤 [+110]

非在研适应症

肺腺癌 [+34]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2013-05-29

TRI1215

靶点-

作用机制

免疫刺激剂

在研机构

北京启辰生生物科技有限公司

原研机构

北京启辰生生物科技有限公司

在研适应症

胶质瘤 [+1]

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期1800-01-20

TRI 1022

靶点-

作用机制

免疫刺激剂

在研机构

北京启辰生生物科技有限公司

原研机构

北京启辰生生物科技有限公司

在研适应症

胶质瘤 [+1]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

项与家族性脑胶质瘤相关的临床试验

ChiCTR2300077403 / RecruitingN/AIIT

Clinical study of Qingxiao method combined with small incision focus resection in the treatment of granulomatous lobular mastitis

开始日期2023-03-01

申办/合作机构-

ChiCTR2200058338 / Recruiting临床4期IIT

Efficacy of ''Zhixiangpi and Baizhi Medicated Thread'' drainage in the treatment of granulomatous mastitis in abscess stage

开始日期2022-03-23

申办/合作机构-

NCT04201457 / Recruiting临床1/2期IIT

Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults

This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressive) or tumors that came back while receiving a similar agent (recurrent). Patients must also have specific genetic mutations including BRAF V600 mutations or BRAF fusion/duplication, with or without neurofibromatosis type 1. Neurofibromatosis type 1 is an inherited genetic condition that causes tumors to grow on nerve tissue. Hydroxychloroquine, works in different ways to stop the growth of tumor cells by killing the cells or stopping them from dividing. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine with trametinib and/or dabrafenib may lower the chance of brain tumors growing or spreading compared to usual treatments.

开始日期2020-01-17

申办/合作机构

National Cancer Institute

100 项与家族性脑胶质瘤相关的临床结果

登录后查看更多信息

100 项与家族性脑胶质瘤相关的转化医学

登录后查看更多信息

0 项与家族性脑胶质瘤相关的专利（医药）

登录后查看更多信息

129

项与家族性脑胶质瘤相关的文献（医药）

2024-10-01·Journal of Diabetes

Major adverse cardiovascular events’ reduction and their association with glucose‐lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health records

Article

作者: Hwang, Wenke ; Kocis, Paul Thomas ; Hsu, Haowen ; Pichardo‐Lowden, Ariana

AbstractBackgroundCardiovascular diseases are a common cause of death among patients with type 2 diabetes (T2DM). Major adverse cardiovascular event (MACE) risks can be significantly reduced under adequate glycemic control (GC). This study aims to identify factors that influence MACE risk among patients with T2DM, including Hemoglobin A1c variability score (HVS) and early use of MACE‐preventive glucose‐lowering medications (GLMs).MethodsWe conducted a longitudinal cohort study to retrospectively review electronic health records between 2011 and 2022. Patients with T2DM ≥18 years without previous stroke or acute myocardial infarction (AMI) were included. Cox regression was utilized to investigate MACE risk factors and compare MACE risk reduction associated with early use of MACE‐preventive GLMs.ResultsA total of 19 685 subjects were included, with 5431 having MACE, including 4453 strokes, 977 AMI, and 1 death. There were 11 123 subjects with good baseline GC. Subjects with good baseline GC had 0.837 (confidence interval [CI]: 0.782–0.895) times lower MACE risk than their counterpart. Subjects with a single MACE‐preventive GLM at baseline with continuous use >365 days showed a decreased MACE hazard ratio (0.681; CI: 0.635–0.731). Among all MACE‐preventive GLMs, semaglutide provided a more significant MACE‐preventive effect.ConclusionsThis study identified that GLM, early GC, and HVS are MACE determinants among patients with T2DM. Novel GLM, adequate GC, and reduction of HVS can benefit MACE outcomes.

image

2024-09-24·Alternative therapies in health and medicine

Clinical Effect of Rehabilitation New Fluid Combined with Sanjie Analgesic Capsules in the Treatment of Granulomatous Mastitis and Thyroiditis and Impact on Immune Indexes of Patients.

Article

作者: Li, Hang ; Zhao, Xin ; Zhao, Haijun ; Xu, Yanbin ; Shang, Yi ; Zhao, Lian

BackgroundIn recent years, China has actively promoted the publicity and promotion of breastfeeding, because breastfeeding is conducive to the healthy growth of babies and conducive to the recovery of maternal health. Behavioral nursing theory holds that individual behavior change is a complex and continuous process, and personalized care is given at different stages of individual behavior change to promote individual behavior change.ObjectiveTo explore the impact of behavioral nursing intervention on the breastfeeding maintenance rate of hospitalized newborns.DesignThis was a prospective cohort study based on the description provided.SettingThis study was conducted in the Department of Pediatrics, Shanghai Six People's Hospital/Shanghai Six People's Hospital Affiliated with Shanghai Jiaotong University School of Medicine, because the author worked in the hospital.ParticipantsA total of 120 cases of parturients in our hospital from January 2021 to December 2022 were chosen and separated into a control group and an observation group through the random number table method. Inclusion criteria: Parturients were full-term single pregnancies, examined in our hospital, and there were no abnormalities in prenatal examination. Exclusion criteria: Parturients with a history of mental illness, accompanied by hepatitis B, three Yang, acquired immune deficiency syndrome and other infectious diseases, and combined with visual and hearing disorders.InterventionsThe control group adopted routine breastfeeding nursing intervention, including training in the prenatal maternity school, instruction in breastfeeding methods during hospital delivery and follow-up after discharge. The observation group adopted behavioral nursing intervention, the corresponding health guidance and nursing methods were formulated and implemented in the second trimester, the third trimester, the hospitalization period of childbirth, and the discharge, and at each stage.Primary Outcome Measures(1) Degree of knowledge about breastfeeding, (2) Efficiency of breastfeeding, (3) Rate of exclusive breastfeeding, (4) Nutritional index, (5) Cognitive ability of newborns, (6) Satisfaction of family members with nursing.ResultsAfter the intervention, the score of feeding knowledge in the observation group was elevated relative to the control group (P < .05). The self-efficacy scores and rates of exclusive breastfeeding in the observation group at 1, 6 weeks, and 6 months after delivery were higher relative to the control group (P < .05). After the intervention, the levels of albumin, albumin, and transferrin in the observation group were higher relative to the control group (P < .05). After the intervention, the scores of the mental development index and psychomotor development index in the observation group were elevated relative to the control group (P < .05).ConclusionBehavioral nursing can effectively improve the effectiveness of breastfeeding and facilitate the health and growth of mothers and newborns, aligning with the broader goals of promoting breastfeeding in healthcare settings.

2024-07-29·Cureus

Granulomatous Mastitis: An Initial Presentation of Undiagnosed Prolactinoma

Article

作者: Salahi, Navid ; McFarlane, Samy I. ; Alkaissi, Hussam ; McFarlane, Samy I ; Kim, Emily J

Granulomatous lobular mastitis (GLM) is a rare, benign inflammatory disease of the breast that shares some physical diagnostic features with breast cancer. GLM has been rarely reported to be associated with prolactinoma. In this report, we present a case of undiagnosed prolactinoma in a 37-year-old woman with its initial presentation as GLM. We discuss the underlying pathophysiologic mechanisms for the development of GLM and the potential immunomodulatory role of prolactin in the development of GLM. We also highlight the need to assess for possible prolactinoma in GLM, which might go undiagnosed as in the case of our patient who did not seek medical attention for her amenorrhea, which is likely due to hyperprolactinemia that might also have other clinical implications on cardiovascular and bone health due to consequent estrogen deficiency.